share_log

Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5

Alliance Global Partners Initiates Coverage On NeuroSense Therapeutics With Buy Rating, Announces Price Target of $7.5

Alliance Global Partners以买入评级开始对NeuroSense Therapeutics进行报道,宣布目标
Benzinga ·  2023/07/17 10:25

Alliance Global Partners analyst James Molloy initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.5.

Alliance Global Partners分析师詹姆斯·莫洛伊开始报道NeuroSense Therapeutics(纳斯达克股票代码:NRSN),评级为买入,并宣布目标股价为7.5美元

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发